BioForm Announces Closing of IPO and Exercise of Underwriters' Over-Allotment Option
November 14 2007 - 4:05PM
PR Newswire (US)
SAN MATEO, Calif., Nov. 14 /PRNewswire-FirstCall/ -- BioForm
Medical, Inc. (NASDAQ:BFRM) announced that on November 13, 2007, it
closed its previously announced initial public offering of
10,000,000 shares and that the underwriters of the offering
exercised their over-allotment option in full and purchased
1,500,000 additional shares of common stock at the public offering
price of $8.00 per share. Including the over-allotment, the company
sold 11,500,000 shares in the offering, resulting in net proceeds
of approximately $83.4 million after deducting the underwriting
discounts and commission and the estimated offering expenses. J.P.
Morgan Securities Inc. and Piper Jaffray & Co. are serving as
joint book-running managers for the offering, with CIBC World
Markets Corp. and Jefferies & Company, Inc. serving as
co-managers. A registration statement relating to these securities
has been filed with, and declared effective by, the U.S. Securities
and Exchange Commission. This press release shall not constitute an
offer to sell or the solicitation of an offer to buy nor shall
there be any sale of these securities in any state or jurisdiction
in which such an offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of
any such state or jurisdiction. A copy of the final prospectus for
the offering may be obtained from the prospectus department of
either J.P. Morgan Securities Inc., 4 Chase Metrotech Center, CS
Level, Brooklyn, NY 11245, or by calling (718) 242-8002; or Piper
Jaffray & Co., 800 Nicollet Mall, Suite 800, Minneapolis, MN
55402 or by calling (877) 371-5212. About BioForm Medical, Inc.:
BioForm Medical, Inc. is a medical aesthetics company headquartered
in San Mateo, California. BioForm's products include Radiesse(R), a
long-lasting filler for use in facial aesthetics and vocal fold
insufficiency, and Coaptite(R) for treating female stress urinary
incontinence which is marketed through a partnership with Boston
Scientific Corporation. CONTACT: Adam Gridley 650/286-4025 Vice
President, Corporate Development BioForm Medical, Inc. DATASOURCE:
BioForm Medical, Inc. CONTACT: Adam Gridley, Vice President,
Corporate Development of BioForm Medical, Inc., +1-650-286-4025 Web
site: http://www.bioformmedical.com/
Copyright
Bioform Medical (MM) (NASDAQ:BFRM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bioform Medical (MM) (NASDAQ:BFRM)
Historical Stock Chart
From Jul 2023 to Jul 2024